Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age \> = 18 years;~* diagnosis of DM type 2;~* pseudophakic patients~* presence of clinically significant DME according to ETDRS guidelines;~* best correct visual acuity (BCVA) between 20/400 and 20/40;~* central macular thickness (CMT) \>= 300 µm measured by spectral domain optical coherence tomography ( Spectralis® Heidelberg). If both eyes of the patient met the elegibility criteria, the eye with worse BCVA at baseline was designated as the study eye.~Exclusion Criteria:~* any treatment of DME in the previous 4 months;~* pan retinal photocoagulation (PRP) in the previous 4 months or antecipated need of PRP for the next 6 months;~* any ophthalmologic surgery performed in the previous 4 months;~* history of pars plana vitrectomy;~* history of open-angle glaucoma or intraocular pressure elevation induced by corticosteroids that required anti-glaucomatous treatment or anti- hypertensive ocular treatment;~* intraocular pressure \>= 21 mmHg;~* patients with characteristics that meet the inclusion criteria, but refused to sign the written general consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 0,01ml dexamethasone solution (Type: EXPERIMENTAL): One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
- 0,03 ml dexamethasone solution (Type: EXPERIMENTAL): One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
- 0,05 ml dexamethasone solution (Type: EXPERIMENTAL): One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).